Seattle-based startup Ozette raised $6 million in seed funding to propel its new AI-driven immune technology. While the company’s main focus is on accelerating analysis of the immune system for improved cancer care, the technology also has the potential to yield insights for infectious diseases, inflammatory disorders, and more.
Ozette, which spun out of nearby Fred Hutch Cancer Research Institute, plans to double its eight person team over the next few months with an eye toward continued growth. The company is hiring across a wide range of disciplines including data science, computational immunology, and software engineering to build a strong culture that is diverse in perspectives and backgrounds.